Table of Contents

Research Articles

• Research Articles

  Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8⁺ T-cell Immunity

  Wenjie Yin, Dorothée Duluc, HyeMee Joo, Yaming Xue, Chao Gu, Zhiqing Wang, Lei Wang, Richard Ouedraogo, Lance Oxford, Amelia Clark, Falguni Parikh, Seunghee Kim-Schulze, LuAnn Thompson-Snipes, Sang-Yull Lee, Clay Beauregard, Jung-Hee Woo, Sandra Zurawski, Andrew G. Sikora, Gerard Zurawski and SangKon Oh

  Cancer Immunol Res October 1 2016 4 (10) 823-834; DOI:10.1158/2326-6066.CIR-16-0128

  
  

  In the U.S., HPV is responsible for more than 26,000 new cancer cases annually. A novel and effective immunotherapeutic vaccine against many types of HPV16-associated cancers was developed that supports targeting vaccines to dendritic cells via CD40.

• Research Articles

  Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

  David B. Page, Jianda Yuan, David Redmond, Y Hanna Wen, Jeremy C. Durack, Ryan Emerson, Stephen Solomon, Zhiwan Dong, Phillip Wong, Christopher Comstock, Adi Diab, Janice Sung, Majid Maybody, Elizabeth Morris, Edi Brogi, Monica Morrow, Virgilio Sacchini, Olivier Elemento, Harlan Robins, Sujata Patil, James P. Allison, Jedd D. Wolchok, Clifford Hudis, Larry Norton and Heather L. McArthur

  Cancer Immunol Res October 1 2016 4 (10) 835-844; DOI:10.1158/2326-6066.CIR-16-0013

  
  

  Tumor cryoablation plus immune checkpoint blockade facilitates antitumor T-cell responses (TCRs) and improves survival in mice. Deep sequencing of TCRs in human early-stage breast cancer tumors revealed T-cell clonality and density and served as a biomarker after cryo-immunotherapy.

• Research Articles

  Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells

  Blanca Homet Moreno, Jesse M. Zaretsky, Angel Garcia-Diaz, Jennifer Tsoi, Giulia Parisi, Lidia Robert, Katrina Meeth, Abibatou Ndoye, Marcus Bosenberg, Ashani T. Weeraratna, Thomas G. Graeber, Begoña Comin-Anduix, Siwen Hu-Lieskovan and Antoni Ribas

  Cancer Immunol Res October 1 2016 4 (10) 845-857; DOI:10.1158/2326-6066.CIR-16-0060

  
  

  Although blockade of the PD-1 pathway has been successfully used to treat various cancers, how this modulates host–tumor interactions is not well understood. Additional mechanisms beyond licensing the final effector phase of killer T cells were identified.

• Research Articles

  VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma

  Xinqi Wu, Anita Giobbie-Hurder, Xiaoyun Liao, Donald Lawrence, David McDermott, Jun Zhou, Scott Rodig and F. Stephen Hodi

  Cancer Immunol Res October 1 2016 4 (10) 858-868; DOI:10.1158/2326-6066.CIR-16-0084

  
  

  Inhibiting both CTLA-4 and VEGF can lead to favorable clinical outcomes. This treatment increased the expression of IL1α, TNFα, IP-10, and the adhesion receptors associated with increased tumor lymphocyte infiltration, and augmented humoral immune responses recognizing tumor targets.

• Research Articles

  Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas

  Adrienne H. Long, Steven L. Highfill, Yongzhi Cui, Jillian P. Smith, Alec J. Walker, Sneha Ramakrishna, Rana El-Etriby, Susana Galli, Maria G. Tsokos, Rimas J. Orentas and Crystal L. Mackall

  Cancer Immunol Res October 1 2016 4 (10) 869-880; DOI:10.1158/2326-6066.CIR-15-0230

  
  

  The efficacy of chimeric antigen receptor (CAR)–modified T cells against solid tumors is not proven. Retinoids are clinically accessible and were found to modulate tumor myeloid-derived suppressor cells, enhancing the efficacy of CAR therapies targeting solid tumors.

• Research Articles

  Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer

  Elizabeth Scheid, Pierre Major, Alain Bergeron, Olivera J. Finn, Russell D. Salter, Robin Eady, Bader Yassine-Diab, David Favre, Yoav Peretz, Claire Landry, Sebastien Hotte, Som D. Mukherjee, Gregory A. Dekaban, Corby Fink, Paula J. Foster, Jeffery Gaudet, Jean Gariepy, Rafick-Pierre Sekaly, Louis Lacombe, Yves Fradet and Ronan Foley

  Cancer Immunol Res October 1 2016 4 (10) 881-892; DOI:10.1158/2326-6066.CIR-15-0189

  
  

  Tumor-associated Tn-MUC1 glycosylated, but not unglycosylated, peptides, induce strong murine immunity. Tn-MUC1 vaccination in macaques and a clinical trial with a Tn-MUC-DC vaccine confirmed the safety and the superiority of Tn-MUC1 vaccination for induction of cellular immune responses.